These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11014938)

  • 1. Treatment of reflux-related and non-reflux-related dysphonia with profound gastric acid inhibition.
    Willems-Bloemer LH; Vreeburg GC; Brummer R
    Folia Phoniatr Logop; 2000; 52(6):289-94. PubMed ID: 11014938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
    Frazzoni M; Grisendi A; Lanzani A; Melotti G; De Micheli E
    Dig Liver Dis; 2002 Feb; 34(2):99-104. PubMed ID: 11926567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
    Frazzoni M; De Micheli E; Grisendi A; Savarino V
    Aliment Pharmacol Ther; 2002 Jan; 16(1):35-9. PubMed ID: 11856076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pH monitoring in patients with benign voice disorders.
    Grøntved AM; West F
    Acta Otolaryngol Suppl; 2000; 543():229-31. PubMed ID: 10909027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laryngopharyngeal sensory deficits in patients with laryngopharyngeal reflux and dysphagia.
    Aviv JE; Liu H; Parides M; Kaplan ST; Close LG
    Ann Otol Rhinol Laryngol; 2000 Nov; 109(11):1000-6. PubMed ID: 11089989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
    Ouatu-Lascar R; Triadafilopoulos G
    Am J Gastroenterol; 1998 May; 93(5):711-6. PubMed ID: 9625114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex juvantibus approach for chronic posterior laryngitis: results of short-term pantoprazole therapy.
    Habermann W; Eherer A; Lindbichler F; Raith J; Friedrich G
    J Laryngol Otol; 1999 Aug; 113(8):734-9. PubMed ID: 10748849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain.
    Xia HH; Lai KC; Lam SK; Hu WH; Wong NY; Hui WM; Lau CP; Chen WH; Chan CK; Wong WM; Wong BC
    Aliment Pharmacol Ther; 2003 Feb; 17(3):369-77. PubMed ID: 12562449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysphonia as an atypical presentation of gastro-oesophageal reflux.
    Weiner GM; Batch AJ; Radford K
    J Laryngol Otol; 1995 Dec; 109(12):1195-6. PubMed ID: 8551156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole.
    Nelson WW; Vermeulen LC; Geurkink EA; Ehlert DA; Reichelderfer M
    Arch Intern Med; 2000 Sep; 160(16):2491-6. PubMed ID: 10979061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
    Park W; Hicks DM; Khandwala F; Richter JE; Abelson TI; Milstein C; Vaezi MF
    Laryngoscope; 2005 Jul; 115(7):1230-8. PubMed ID: 15995512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease.
    Gremse D; Winter H; Tolia V; Gunasekaran T; Pan WJ; Karol M; Chiu YL; Pilmer B; Book L
    J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S319-26. PubMed ID: 12607792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.
    Oda K; Iwakiri R; Hara M; Watanabe K; Danjo A; Shimoda R; Kikkawa A; Ootani A; Sakata H; Tsunada S; Fujimoto K
    Dig Dis Sci; 2005 Oct; 50(10):1921-6. PubMed ID: 16187198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
    Calabrese C; Liguori G; Gabusi V; Gionchetti P; Rizzello F; Straforini G; Brugnera R; Di Febo G
    Aliment Pharmacol Ther; 2008 Jul; 28(2):250-5. PubMed ID: 18485128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
    Bautista J; Fullerton H; Briseno M; Cui H; Fass R
    Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
    Miner P
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():20-9. PubMed ID: 15496215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.